Key Takeaways from the Complicated Intra-Abdominal Infections Pipeline Report
-
Over 15+ companies and 15+ pipeline drugs Complicated Intra-Abdominal Infections pipeline therapies are in various stages of development, and their anticipated acceptance in the Complicated Intra-Abdominal Infections market would significantly increase market revenue.
-
Leading Complicated Intra-Abdominal Infections companies developing novel drug candidates to improve the MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and many others.
-
Promising Alpha-Antitrypsin Deficiency Areata pipeline therapies in various stages of development include AQST-108, NS-002, and others.
Complicated Intra-Abdominal Infections Overview
Complicated intra-abdominal infections (cIAI) are infections that extend beyond the source organ into the peritoneal space as a result of perforation or other damage to the gastrointestinal tract. The disease is associated with either abscess formation or peritonitis. This type of infection is usually polymicrobial and is caused by Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria.
Complicated Intra-Abdominal Infections Pipeline Therapies and Key Companies
-
Sulopenem: Interim Therapeutics
-
Avibactam/aztreonam: AbbVie
And many others.
DelveInsight’s Report covers around 15 + products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
The complicated Intra-Abdominal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
intravitreal
-
Subretinal
-
Topical.
-
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
-
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Alpha-Antitrypsin Deficiency Areata Pipeline Report
-
Coverage: Global
-
Key Complicated Intra-Abdominal Infections Companies: MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and many others.
-
Key Complicated Intra-Abdominal Infections Pipeline Therapies: Sulopenem, Avibactam/aztreonam, and many others.
-
Find out more about the Complicated Intra-Abdominal Infections treatment options in development @ Complicated Intra-Abdominal Infections Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services